What is the potency classification of clobetasone butyrate?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 23, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Clobetasone Butyrate Potency Classification

Clobetasone butyrate 0.05% is classified as a moderate potency (Class 4-5) topical corticosteroid.

Evidence-Based Classification

Multiple high-quality guidelines consistently categorize clobetasone butyrate as a moderate potency steroid:

  • UK Expert Consensus (2015): Explicitly lists clobetasone butyrate 0.05% (Eumovate®) under the "Moderate" potency category in their topical corticosteroid classification table 1

  • Comparative Potency Studies: Research demonstrates that clobetasone butyrate 0.05% has equivalent vasoconstrictive potency to betamethasone valerate 0.1% and beclomethasone dipropionate 0.025%, both established moderate potency steroids 2

Clinical Context

The moderate potency classification places clobetasone butyrate in the middle tier of the seven-class topical steroid hierarchy:

  • Below it: Mild steroids like hydrocortisone 1% (Class 6-7)
  • Above it: Potent steroids like betamethasone valerate 0.1% (Class 3) and very potent steroids like clobetasol propionate 0.05% (Class 1)

Important Clinical Distinctions

Do not confuse clobetasone butyrate with clobetasol propionate - these are entirely different molecules with vastly different potencies:

  • Clobetasol propionate 0.05% = Very potent (Class 1)
  • Clobetasone butyrate 0.05% = Moderate potency (Class 4-5)

Safety Profile

The moderate potency classification has practical implications for safety. Clinical trials involving over 3,500 patients demonstrate that clobetasone butyrate 0.05% has:

  • Negligible systemic absorption even under extreme conditions
  • Almost no effect on HPA axis function
  • No clinically significant difference from hydrocortisone 1% in terms of skin thinning potential with short-term use 3

This favorable safety profile, combined with superior efficacy to hydrocortisone 1%, makes it appropriate for pharmacy-level (OTC) availability in some countries for short-term management of acute eczema and allergic dermatitis in adults and children aged 10 or older 3.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.